Viking Therapeutics, Inc.(VKTX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

VKTX Viking Therapeutics, Inc.

已收盘 07-26 16:00:00 EDT

65.98

+1.30

+2.01%

盘后66.00

+0.02+0.03%

19:58 EDT

最高70.96	最低64.50	成交量929.68万
今开65.62	昨收64.68	日振幅9.99%
总市值73.10亿	流通市值69.19亿	总股本1.11亿
成交额6.30亿	换手率8.87%	流通股本1.05亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"VKTX","market":"US","secType":"STK","nameCN":"Viking Therapeutics, Inc.","latestPrice":65.98,"timestamp":1722024000000,"preClose":64.68,"halted":0,"volume":9296767,"hourTrading":{"tag":"盘后","latestPrice":66,"preClose":65.98,"latestTime":"19:58 EDT","volume":180763,"amount":11921988.4981,"timestamp":1722038332999},"delay":0,"floatShares":104858620,"shares":110796200,"eps":-0.935276,"marketStatus":"已收盘","marketStatusCode":5,"change":1.3,"latestTime":"07-26 16:00:00 EDT","open":65.62,"high":70.96,"low":64.5001,"amount":629630889.52093,"amplitude":0.099875,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.935276,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1722240000000},"adr":0,"listingDate":1430280000000,"adjPreClose":64.68,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":65.77,"preClose":64.68,"latestTime":"09:29 EDT","volume":91201,"amount":6132865.053590001,"timestamp":1722000588778},"postHourTrading":{"tag":"盘后","latestPrice":66,"preClose":65.98,"latestTime":"19:58 EDT","volume":180763,"amount":11921988.4981,"timestamp":1722038332999},"volumeRatio":1.520397,"impliedVol":0.9001,"impliedVolPercentile":0.4762},"requestUrl":"/m/hq/s/VKTX","defaultTab":"news","newsList":[{"id":"2454130113","title":"隔夜美股全复盘(7.27)| PCE超预期，三大股指高开高走，中概股指数涨1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2454130113","media":"格隆汇","labels":["Economic Data"],"top":-1,"share":"https://www.laohu8.com/m/news/2454130113?lang=zh_cn&edition=full","pubTime":"2024-07-27 06:45","pubTimestamp":1722033910,"startTime":"0","endTime":"0","summary":"PCE超预期，三大股指高开高走，中概股指数涨1%","market":"sg","thumbnail":"https://img7.gelonghui.com/column/2/140.png","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/140.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/884050","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Economic Data","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["IE00B3SWFQ91.USD","IE00BMPRXN33.USD","LU0820561818.USD","BK4581","JPM","XPEV","NVDA","AAPL","BK4579","LU2360032135.SGD","IE00BN8TJ469.HKD","IE000M9KFDE8.USD","SG9999015986.USD","NVO","SG9999004220.SGD","SQ","LU1066051811.HKD","META","LU","GOOGL","LU0211328371.USD","EDU","PDD","LU2125154935.USD","PYPL","LU2237443978.SGD","IE00BWXC8680.SGD","BK4515","AMZN","JD","LU0689472784.USD","LU0471298694.HKD","IE00BHPRN162.USD","LU0198837287.USD","DIS","LI","LU1988902786.USD","LU0417517546.SGD","TSM","IE00BFTCPJ56.SGD","TTTN","IE00B1XK9C88.USD","IE00BFSS7M15.SGD","MSFT","BABA","03145","LKNCY","IE00B5949003.HKD","LU0878005551.USD","IE00B4YYXB79.USD","IE00BJLML261.HKD","LU2237443382.USD","BILI","LU0096362180.USD","VKTX","IE00B5TLWC47.USD","WMT","BK4575","AVGO","UNH","LU0143863198.USD","LU0143863784.USD","BK4516","LU2237443549.SGD","LU0820561909.HKD","LU2237443622.USD","QCOM","IE0034235303.USD","TSLA","NIO"],"gpt_icon":1},{"id":"2454477663","title":"Viking Therapeutics, Inc.盘中异动 股价大涨5.40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2454477663","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2454477663?lang=zh_cn&edition=full","pubTime":"2024-07-26 21:35","pubTimestamp":1722000946,"startTime":"0","endTime":"0","summary":"北京时间2024年07月26日21时35分，Viking Therapeutics, Inc.股票出现异动，股价大幅拉升5.40%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.08%。其相关个股中，Windtree Therapeutics, Inc.、Nutriband Inc C/Wts 、Cel-Sci Corporation涨幅较大，Windtree Therapeutics, Inc.、Novabay Pharmaceuticals, Inc.、Cel-Sci Corporation较为活跃，换手率分别为3126.61%、101.69%、32.76%，振幅较大的相关个股有Windtree Therapeutics, Inc.、Cel-Sci Corporation、Promis Neurosciences Inc.，振幅分别为43.16%、39.67%、20.82%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240726213546af945934&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240726213546af945934&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VKTX","BK4585","LENZ","BK4588","BK4139"],"gpt_icon":1},{"id":"2454349572","title":"盘前：纳指期货涨1.3% 6月PCE重磅来袭","url":"https://stock-news.laohu8.com/highlight/detail?id=2454349572","media":"环球市场播报","labels":["Economic Data"],"top":-1,"share":"https://www.laohu8.com/m/news/2454349572?lang=zh_cn&edition=full","pubTime":"2024-07-26 20:28","pubTimestamp":1721996909,"startTime":"0","endTime":"0","summary":"美股股指期货周五盘前走强，美国国内生产总值超出预期后，投资者聚焦美国个人消费支出数据，这将影响市场对美联储降息时间的定价。　　截至发稿，道指期货涨0.8%，标普500指数期货涨0.9%，纳指期货涨1.3%。　　德国DAX指数涨0.3%，英国富时100指数涨0.7%，法国CAC40指数涨0.9%，欧洲斯托克50指数涨0.9%。　　美国经济分析局周四报告称，4月至6月期间美国GDP增长年率为2.8%，而上一季增长率为1.4%，预期的增长率为2%。","market":"us","thumbnail":"https://n.sinaimg.cn/finance/transform/66/w550h316/20240726/6e82-90da8ad80f3a00ea5f5bf220c6b0f67b.jpg","type":0,"news_type":0,"thumbnails":["https://n.sinaimg.cn/finance/transform/66/w550h316/20240726/6e82-90da8ad80f3a00ea5f5bf220c6b0f67b.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2024-07-26/doc-incfnkrz4102030.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Economic Data","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["TQQQ","NQmain","QID","PSQ","BK4550",".IXIC","QLD","BK4593","SQQQ","NVDA","BK4581","MNQmain","TSLA","BK4534","BK4588","BK4585","NIO","BK4561","XPEV","VKTX","COIN"],"gpt_icon":1},{"id":"2454647315","title":"Viking Therapeutics(VKTX)盘前升逾6% 减肥药VK2735提前推进至第三期","url":"https://stock-news.laohu8.com/highlight/detail?id=2454647315","media":"金吾财讯","labels":["Product Release"],"top":-1,"share":"https://www.laohu8.com/m/news/2454647315?lang=zh_cn&edition=full","pubTime":"2024-07-26 17:30","pubTimestamp":1721986255,"startTime":"0","endTime":"0","summary":"金吾财讯｜Viking Therapeutics(VKTX)盘前股价走高，暂升6.46%，报68.86美元。消息面上，Viking Therapeutics公布的减肥药注射剂VK2735开发进程加快，在获得美国食药监局FDA的书面回复后，决定将其提前推进到第三期、也是终期临床试验阶段。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210810/Yzk2MTU4OTVjMjIwMzU3MzgyMjUzNg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/Yzk2MTU4OTVjMjIwMzU3MzgyMjUzNg==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"278238","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VKTX","BK4585","BK4139","LENZ","BK4588"],"gpt_icon":1},{"id":"1136187782","title":"不止“减肥药双雄”，基金经理点名存在估值机会的股票，并称市场大到可以容纳三到四家公司","url":"https://stock-news.laohu8.com/highlight/detail?id=1136187782","media":"老虎资讯综合","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/1136187782?lang=zh_cn&edition=full","pubTime":"2024-07-26 11:45","pubTimestamp":1721965537,"startTime":"0","endTime":"0","summary":"减肥药在过去一年左右引起了投资者的兴趣，并撼动了其他行业。Tema ETFs的基金经理Yuri Khodjamirian表示，这两家公司构成了一个“非常强大的双头垄断”。“我认为市场大到可以容纳三到四家公司，即使是现在已经存在的市值，但市场正在试图找出第三或第四个玩家，而一个重大的突破可能是口服GLP-1药物，”他说。GLP-1是一种在肠道中释放的激素，能刺激胰岛素分泌，延缓胃排空并向大脑传递饱腹感。他说，目前生物技术股票存在“估值机会”，但也警告了风险。","market":"us","thumbnail":"https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO","VKTX","AMGN","LLY"],"gpt_icon":1},{"id":"2454355980","title":"有望打破双巨头垄断？“减肥药新星”Viking股价年内暴涨247%","url":"https://stock-news.laohu8.com/highlight/detail?id=2454355980","media":"格隆汇","labels":["Product Release"],"top":-1,"share":"https://www.laohu8.com/m/news/2454355980?lang=zh_cn&edition=full","pubTime":"2024-07-26 09:25","pubTimestamp":1721957152,"startTime":"0","endTime":"0","summary":"礼来市值蒸发1200亿美元","market":"hk","thumbnail":"https://img3.gelonghui.com/cf5c3-80d27774-ed63-490a-977d-1ea8fc925c87.jpg?guru_height=852&guru_width=1280","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/cf5c3-80d27774-ed63-490a-977d-1ea8fc925c87.jpg?guru_height=852&guru_width=1280"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/880989","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK4588","LU0238689110.USD","IE0002141913.USD","IE00BJLML261.HKD","LU1057294990.SGD","LU0320765059.SGD","BK4585","LU0198837287.USD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","LU0640476718.USD","LU0882574139.USD","LU1069344957.HKD","LU0417517546.SGD","LU0708995401.HKD","IE0004445239.USD","BK4139","LU0096364046.USD","LU0256863902.USD","BK4534","IE00B1BXHZ80.USD","LU0109391861.USD","LU0672654240.SGD","LU0820561909.HKD","BK4533","LU0823416689.USD","LU1280957306.USD","LU0456855351.SGD","LU0097036916.USD","LU1061106388.HKD","LU0289739699.SGD","GB00BDT5M118.USD","LU0882574055.USD","LU0114720955.EUR","VKTX","LU0471298777.SGD","BK4007","LU1267930730.SGD","LU1551013342.USD","LU1551013425.SGD","IE00BFTCPJ56.SGD","LU0820561818.USD","IE00B4R5TH58.HKD","BK4516","LU0061475181.USD","LU0058720904.USD","LU0122379950.USD","NVO","LLY","IE00BK4W5L77.USD"],"gpt_icon":1},{"id":"1155648411","title":"Viking Therapeutics暴涨近30%，最新研究可能撼动减肥药市场，吓坏两大市场巨头","url":"https://stock-news.laohu8.com/highlight/detail?id=1155648411","media":"老虎资讯综合","labels":["analysis"],"top":-1,"share":"https://www.laohu8.com/m/news/1155648411?lang=zh_cn&edition=full","pubTime":"2024-07-26 07:36","pubTimestamp":1721950589,"startTime":"0","endTime":"0","summary":"$Viking Therapeutics$ 的股票在周四飙升28.31%，因为该公司宣布正在研究其减肥药的每月剂量。此前，Viking计划进行二期B阶段的研究。两家公司分别通过Zepbound和Wegovy主导减肥药市场，但它们的每周注射药物面临短缺，这意味着竞争对手有机会进入市场。而Viking是首个宣布潜在每月注射方案的公司。Viking Therapeutics股票表现强劲 Viking Therapeutics的消息对礼来的股票特别不利。他对Viking Therapeutics的股票给予了“优于大盘”的评级。口服减肥药市场也在升温。","market":"us","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Viking Therapeutics减肥药物研究取得重大进展,股价大涨28%","news_tag":"analysis","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LLY","NVO","VKTX"],"gpt_icon":1},{"id":"2454809437","title":"BUZZ--美国股票走势-环球医疗服务公司、罗伯特-哈弗公司、拉扎德公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2454809437","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2454809437?lang=zh_cn&edition=full","pubTime":"2024-07-26 00:18","pubTimestamp":1721924332,"startTime":"0","endTime":"0","summary":"        *      个股走势的 Eikon 搜索字符串：[STXBZ］        *      The Day Ahead 新闻通讯：          *      The Morning News Call时事通讯：      7月25日 - 华尔街主要股指周四涨跌不一，原因是投资者评估了强于预期的国内生产总值数据，并在上一交易日遭遇科技股重挫后保持谨慎。美东时间11:52，道琼斯工业平均指数  上涨0.85%，报40192.32点。标普500指数  上涨0.43%，报5450.63点；纳斯达克综合指数  上涨0.11%，报17361.436点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNX","WST","RHI","WBD","NOW","DXD","NYCB","KDP","NVDA","MOH","KLAC","LINE","TER","BC","ABBV","AMP","NQmain","TQQQ","DOW","LAZ","MXL","VKTX","ALGM","ALGN","HON","MAS","WTW","HAS","RCL","MNQmain","SDOW","SQQQ",".SPX","HP",".DJI","NDAQ","UHS","RTX",".IXIC","BUZZ","POOL","MU","AMD"],"gpt_icon":1},{"id":"2454877381","title":"Viking Therapeutics, Inc.2024财年第二财季实现净利润-22.25百万美元，同比减少15.70%","url":"https://stock-news.laohu8.com/highlight/detail?id=2454877381","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2454877381?lang=zh_cn&edition=full","pubTime":"2024-07-25 22:12","pubTimestamp":1721916755,"startTime":"0","endTime":"0","summary":"7月25日，Viking Therapeutics, Inc.公布财报，公告显示公司2024财年第二财季净利润为-22.25百万美元，同比减少15.70%；其中营业收入为0.00美元，每股基本收益为-0.20美元。从资产负债表来看，Viking Therapeutics, Inc.总负债25.86百万美元，其中短期债务334000.00美元，资产负债比为0.37，流动比率为0.38。机构评级：截至2024年7月25日，当前有11家机构对Viking Therapeutics, Inc.目标价做出预测，其中目标均价为113.55美元，其中最低目标价为90.00美元，最高目标价为138.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240725221246955a5c1a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240725221246955a5c1a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","VKTX"],"gpt_icon":0},{"id":"2454879437","title":"Viking Therapeutics, Inc.股价飙升15.16% 市值涨9.7亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2454879437","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2454879437?lang=zh_cn&edition=full","pubTime":"2024-07-25 21:31","pubTimestamp":1721914308,"startTime":"0","endTime":"0","summary":"北京时间2024年07月25日21时31分，Viking Therapeutics, Inc.股票出现异动，股价快速拉升15.16%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.23%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407252131489eea103b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407252131489eea103b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","VKTX","LENZ","BK4588","BK4139"],"gpt_icon":0},{"id":"2454274875","title":"BUZZ--美国股票走势-艾伯维、RTX、莫利纳","url":"https://stock-news.laohu8.com/highlight/detail?id=2454274875","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2454274875?lang=zh_cn&edition=full","pubTime":"2024-07-25 21:14","pubTimestamp":1721913271,"startTime":"0","endTime":"0","summary":"        *      个股异动的 Eikon 搜索字符串：[STXBZ］        *      The Day Ahead 新闻通讯：          *      The Morning News Call时事通讯：      7月25日 - 美国股指期货周四收窄跌幅，此前耐用品数据弱于预期，提振了市场对美联储提前降息的希望。美东时间9:01，道指电子盘  上涨0.12%，报40159点。标普500指数  上涨0.02%，报5473.25点；纳斯达克100指数  上涨0.09%，报19220.25点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EW","LU0316494557.USD","WBD","IE00BZ199S13.USD","IE00BLSP4239.USD","LU1267930813.SGD","LU2286300806.USD","IE00BBT3K403.USD","AMD","RTX","NYCB","IE00BFSS7M15.SGD","SG9999014005.SGD","BUZZ","WST","AVGO","RCL","NVDA","LU0348723411.USD","VKTX","IE00B19Z9P08.USD","IE00B1BXHZ80.USD","KLAC","IE00BN8TJ469.HKD","NOW","LU0061474960.USD","LU0965509283.SGD","LU0077335932.USD","LU1880398471.USD","TER","SG9999014013.SGD","MOH","BC","LU0823414478.USD","IE00B7KXQ091.USD","DOW","HAS","IE00B19Z9505.USD","IE00BMPRXR70.SGD","LU0965508806.USD","HON","LU0320765059.SGD","IE0034235303.USD"],"gpt_icon":1},{"id":"2454820153","title":"BUZZ--美国股票走势-KLA Corp、IMB、ServiceNow","url":"https://stock-news.laohu8.com/highlight/detail?id=2454820153","media":"Reuters","labels":["Business Data"],"top":-1,"share":"https://www.laohu8.com/m/news/2454820153?lang=zh_cn&edition=full","pubTime":"2024-07-25 20:28","pubTimestamp":1721910530,"startTime":"0","endTime":"0","summary":"        *      个股走势的 Eikon 搜索字符串：[STXBZ］        *      The Day Ahead 新闻通讯：          *      The Morning News Call时事通讯：      7月25日 - 纳斯达克指数和标普500指数期货周四下滑，一天前，大型科技股的大幅下挫导致该指数创下自2022年以来的最大跌幅，投资者正在关注一系列财报发布和关键经济数据。美东时间8:10，道指电子盘  下跌 0.03%，报 40,098 点。标普500指数小型股  下跌0.20%，报5461.25点；纳斯达克100指数小型股  下跌0.27%，报19150.5点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Business Data","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2458330243.SGD","LU0823421333.USD","HON","LU2023250843.SGD","IE00BMPRXR70.SGD","BK4573","NOW","LU2458330169.SGD","LU0820561909.HKD","IE00BFSS7M15.SGD","LU0320765059.SGD","LU0823421416.USD","IBM","LU0170899867.USD","KLAC","LU1430594728.SGD","LU1585245621.USD","VKTX","TER","EW","HAS","LU0061474705.USD","LU0823434583.USD","DOW","BUZZ","IE00BFSS8Q28.SGD","LU0823434740.USD","LU0889566641.SGD","BK4581","LU0689472784.USD","LU0348723411.USD","WBD","LU0069063385.USD","BK4575","IE00B19Z9P08.USD","BK4579","CMG","LU0057025933.USD","BK4112","LU2065169927.USD","LU0096364046.USD","LU0109391861.USD"],"gpt_icon":1},{"id":"2454382265","title":"“减肥药新贵”Viking(VKTX.US)新药进入研发后期，“诺礼”股价受惊下挫","url":"https://stock-news.laohu8.com/highlight/detail?id=2454382265","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2454382265?lang=zh_cn&edition=full","pubTime":"2024-07-25 19:44","pubTimestamp":1721907894,"startTime":"0","endTime":"0","summary":"智通财经获悉，周四，“减肥药双雄”礼来和诺和诺德股价在盘前均跌超2%，此前Viking Therapeutics宣布计划在今年晚些时候开始其肥胖候选药物VK2735的后期试验。Viking周三公布了2024年第二季度财报，优于预期的业绩推动该公司股价在周四盘前交易中上涨近17%。Viking对VK2735的计划表明其研发的时间表加快了。与此同时，降糖减肥治疗市场竞争激烈。而罗氏今年以27亿美元收购美国减肥药开发商Carmot Therapeutics，进入肥胖治疗市场。但这些公司受该消息影响不大，盘前股价基本持稳。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1155759.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VKTX","BK4139","BK4588","BK4585"],"gpt_icon":0},{"id":"2454475158","title":"BUZZ-肥胖症药物试验加速，Viking Therapeutics 公司业绩大增","url":"https://stock-news.laohu8.com/highlight/detail?id=2454475158","media":"Reuters","labels":["Product Release"],"top":-1,"share":"https://www.laohu8.com/m/news/2454475158?lang=zh_cn&edition=full","pubTime":"2024-07-25 17:52","pubTimestamp":1721901142,"startTime":"0","endTime":"0","summary":"    7月25日 - ** Viking Therapeutics   股价盘前上涨20.15%至60.57美元** 该公司表示，它将把肥胖症药物VK2735 的试验提前到后期开发阶段，绕过第二个中期试验。** 在中期试验  中，该药物显示体重最多可减轻 ~15** Truist表示，这将缩短约12个月的上市时间** 在未来的试验中，将对每月一次的皮下注射药物剂量进行评估。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0094547139.USD","IE00BJJMRZ35.SGD","BK4588","IE00B4R5TH58.HKD","IE0002141913.USD","LU1551013342.USD","BK4534","IE00B1BXHZ80.USD","LU1551013425.SGD","BK4007","LENZ","LU0640476718.USD","LU0823416689.USD","LU0882574055.USD","LU0256863811.USD","LU1623119135.USD","BK4516","LU0289739699.SGD","IE0004445239.USD","LU1712237335.SGD","LU0061475181.USD","LU1280957306.USD","LU0320765059.SGD","VKTX","IE00BFTCPJ56.SGD","IE0009355771.USD","LU0385154629.USD","LU0471298694.HKD","IE00B2B36J28.USD","LU0708995401.HKD","IE00BJT1NW94.SGD","LU1064131342.USD","LU0943347566.SGD","LU0079474960.USD","LU0471298777.SGD","LU1035775433.USD","BK4581","LU0820561818.USD","LU1804176565.USD","LU0058720904.USD","IE00BK4W5L77.USD","LU0198837287.USD","LU0672654240.SGD","LU1023059063.AUD","BUZZ","LU1057294990.SGD","LU0689472784.USD","LU1061106388.HKD","LU1069344957.HKD"],"gpt_icon":1},{"id":"1196111206","title":"生物技术公司维京治疗Q2业绩超预期，减肥药效果良好，盘后涨超20%","url":"https://stock-news.laohu8.com/highlight/detail?id=1196111206","media":"老虎资讯综合","labels":["Business Data","movement"],"top":-1,"share":"https://www.laohu8.com/m/news/1196111206?lang=zh_cn&edition=full","pubTime":"2024-07-25 11:06","pubTimestamp":1721876784,"startTime":"0","endTime":"0","summary":"当地时间周三，维京治疗公布了二季度业绩，每股亏损 20 美分，超出了分析师普遍预期的 27 美分，盘后股价涨超20%。业绩显示，维京治疗二季度净亏损为 2230 万美元，2023 年同期为 1920 万美元。截至 2024 年 6 月 30 日的三个月内，净亏损的增加主要是由于研发支出和一般及行政支出的增加所致，这一增长部分被与 2023 年同期相比增加的利息收入所抵消。今年二月，受到公司披露减肥药VK2735的积极临床试验数据推动，维京治疗股价单日大涨121.02%。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"维京治疗公司减肥药VK2735临床试验取得突破性进展","news_tag":"Business Data,movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VKTX"],"gpt_icon":1},{"id":"2454851103","title":"维京治疗公司（Viking Therapeutics Inc）公布截至 6 月的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2454851103","media":"Reuters","labels":["express"],"top":-1,"share":"https://www.laohu8.com/m/news/2454851103?lang=zh_cn&edition=full","pubTime":"2024-07-25 05:58","pubTimestamp":1721858302,"startTime":"0","endTime":"0","summary":"   * Viking Therapeutics Inc   报告了截至6月底的季度调整后每股亏损20美分，低于去年同期的每股收益-19美分。十二位分析师对该季度的平均预期是每股亏损 27 美分。华尔街预期为每股-32美分至-17美分。* Viking Therapeutics Inc 报告的季度每股收益为亏损 20 美分。* 该公司当季亏损 2225 万美元。* Viking Therapeutics Inc 的股价本季度下跌了 2.8%，今年迄今为止上涨了 176.9%。7月24日 - 预测变化   * 过去三个月，分析师的平均盈利预期下降了约 4.7%。华尔街对 Viking Therapeutics Inc 的 12 个月目标价中位数为 116.00 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","VKTX","LENZ","BK4585"],"gpt_icon":0},{"id":"2454511058","title":"维京治疗公司（Viking Therapeutics Inc）公布截至 6 月的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2454511058","media":"Reuters","labels":["express"],"top":-1,"share":"https://www.laohu8.com/m/news/2454511058?lang=zh_cn&edition=full","pubTime":"2024-07-25 05:58","pubTimestamp":1721858302,"startTime":"0","endTime":"0","summary":"   * Viking Therapeutics Inc   报告了截至6月底的季度调整后每股亏损20美分，低于去年同期的每股收益-19美分。十二位分析师对该季度的平均预期是每股亏损 27 美分。华尔街预期为每股-32美分至-17美分。* Viking Therapeutics Inc 报告的季度每股收益为亏损 20 美分。* 该公司当季亏损 2225 万美元。* Viking Therapeutics Inc 的股价本季度下跌了 2.8%，今年迄今为止上涨了 176.9%。7月24日 - 预测变化   * 过去三个月，分析师的平均盈利预期下降了约 4.7%。华尔街对 Viking Therapeutics Inc 的 12 个月目标价中位数为 116.00 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","LENZ","VKTX","BK4139"],"gpt_icon":0},{"id":"2453744899","title":"Viking Therapeutics Inc    预计每股亏损 27 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2453744899","media":"Reuters","labels":["preview"],"top":-1,"share":"https://www.laohu8.com/m/news/2453744899?lang=zh_cn&edition=full","pubTime":"2024-07-23 06:37","pubTimestamp":1721687836,"startTime":"0","endTime":"0","summary":"   * Viking Therapeutics Inc    将于7月24日公布截至2024年6月30日的财报，预计季度收入将保持不变。*    * LSEG分析师对Viking Therapeutics Inc的平均预期是每股亏损27美分。* 华尔街对 Viking Therapeutics Inc 的 12 个月目标价中值为 116.00 美元，高于其上一交易日 51.71 美元的收盘价。7月22日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。(如对本报告中的数据有任何疑问，请联系 Estimates.Support@lseg.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VKTX","LENZ"],"gpt_icon":0},{"id":"2452861160","title":"BUZZ-罗氏试验性药物的早期数据令肥胖药生产商望而却步","url":"https://stock-news.laohu8.com/highlight/detail?id=2452861160","media":"Reuters","labels":["Business Data"],"top":-1,"share":"https://www.laohu8.com/m/news/2452861160?lang=zh_cn&edition=full","pubTime":"2024-07-18 01:11","pubTimestamp":1721236299,"startTime":"0","endTime":"0","summary":"** 瑞士制药商罗氏  报告了一种试验性每日一次肥胖药CT-996的早期数据 ，该药帮助 患者在四周内平均减轻了6.1%的体重。** Structure 公司的口服肥胖症药物在一项中期研究中帮助患者平均减轻了 6.2% 的体重，而 VKTX 公司预计将于今年开始对其片剂进行中期研究。** 经纪公司 BMO Capital 称，虽然罗氏的早期数据似乎与 GPCR 和 LLY 的实验药物相当，但要进行有意义的比较，还需要详细的耐受性数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Business Data","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1280957306.USD","IE00BFTCPJ56.SGD","LU0708995401.HKD","LU1035775433.USD","LU0061475181.USD","LU1712237335.SGD","BK4007","LU0256863902.USD","LU0466842654.USD","LU0094547139.USD","LU1623119135.USD","LLY","LU0058720904.USD","LU0672654240.SGD","LU1057294990.SGD","BK4533","IE00B2B36J28.USD","LU0689472784.USD","IE0009355771.USD","LU0820561909.HKD","LU1064131342.USD","LU0820561818.USD","LU0320765059.SGD","LU0097036916.USD","LU1267930730.SGD","BK4581","LU1023059063.AUD","LU0385154629.USD","LU0471298777.SGD","LU0823416689.USD","LU0456855351.SGD","IE00BJT1NW94.SGD","LU0289739699.SGD","BK4534","LU0238689110.USD","GPCR","LU0640476718.USD","LU0882574139.USD","IE00BK4W5L77.USD","BK4516","LU0417517546.SGD","IE00B4R5TH58.HKD","LU1069344957.HKD","BUZZ","LU0109391861.USD","LU0198837287.USD","LU0122379950.USD","IE00BK4W5M84.HKD","VKTX","IE00B1BXHZ80.USD"],"gpt_icon":1},{"id":"1167017119","title":"罗氏口服减肥药临床试验取得积极结果！减肥药概念股闻讯下挫","url":"https://stock-news.laohu8.com/highlight/detail?id=1167017119","media":"老虎资讯综合","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/1167017119?lang=zh_cn&edition=full","pubTime":"2024-07-17 21:41","pubTimestamp":1721223718,"startTime":"0","endTime":"0","summary":"7月17日，罗氏控股涨近8%，公司称其口服减肥药临床试验取得积极结果；受此消息影响，$诺和诺德(NVO)$、$礼来(LLY)$、Viking减肥药概念股集体下挫。","market":"us","thumbnail":"https://static.tigerbbs.com/5d1fe578ee46cbe0d24c33435ff25ae5","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5d1fe578ee46cbe0d24c33435ff25ae5"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0882574055.USD","BK4585","IE00BJLML261.HKD","LU0097036916.USD","LU0820561909.HKD","LU0471298694.HKD","BK4532","LU1061106388.HKD","LU0122379950.USD","LLY","BK4534","VKTX","NVO","IE00BK4W5L77.USD","IE00BK4W5M84.HKD","LU0466842654.USD","IE00B1BXHZ80.USD","LU0096364046.USD","RHHBY","LU1804176565.USD","LU0689472784.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vikingtherapeutics.com","stockEarnings":[{"period":"1week","weight":0.291},{"period":"1month","weight":0.3531},{"period":"3month","weight":-0.1296},{"period":"6month","weight":2.0267},{"period":"1year","weight":3.5294},{"period":"ytd","weight":2.4756}],"compareEarnings":[{"period":"1week","weight":-0.0258},{"period":"1month","weight":-0.0118},{"period":"3month","weight":0.0593},{"period":"6month","weight":0.1046},{"period":"1year","weight":0.182},{"period":"ytd","weight":0.1328}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Viking Therapeutics, Inc.于2012年9月24号在特拉华州成立。该公司是一个临床阶段的生物制药公司，致力于开发新的，第一类或最好的新陈代谢和内分泌失调类疗法。该公司拥有全球独家权利基于许可的配体小分子组合在五个候选药物在临床试验或临床前研究。公司的主导临床程序是VK0612，它是进入2b期临床试验为2型全球最大的健康挑战之一的治疗糖尿病疾病口服药物，它在同药物中排列第一。公司的第二临床程序vk5211，可把口服的候选药物送入第二阶段临床试验治疗一种复杂的疾病特点的不受控制的肌肉质量下降癌症恶病。VK5211是一种非甾体选择性雄激素受体调节剂，或SARM。","yearOnYearQuotes":[{"month":1,"riseRate":0.555556,"avgChangeRate":0.031825},{"month":2,"riseRate":0.555556,"avgChangeRate":0.264573},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.020024},{"month":4,"riseRate":0.444444,"avgChangeRate":-0.000523},{"month":5,"riseRate":0.3,"avgChangeRate":0.094367},{"month":6,"riseRate":0.4,"avgChangeRate":-0.023196},{"month":7,"riseRate":0.5,"avgChangeRate":0.009413},{"month":8,"riseRate":0.444444,"avgChangeRate":0.019922},{"month":9,"riseRate":0.333333,"avgChangeRate":0.070513},{"month":10,"riseRate":0.222222,"avgChangeRate":-0.002105},{"month":11,"riseRate":0.555556,"avgChangeRate":0.0115},{"month":12,"riseRate":0.666667,"avgChangeRate":0.206888}],"exchange":"NASDAQ","name":"Viking Therapeutics, Inc.","nameEN":"Viking Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Viking Therapeutics, Inc.(VKTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Viking Therapeutics, Inc.(VKTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Viking Therapeutics, Inc.,VKTX,Viking Therapeutics, Inc.股票,Viking Therapeutics, Inc.股票老虎,Viking Therapeutics, Inc.股票老虎国际,Viking Therapeutics, Inc.行情,Viking Therapeutics, Inc.股票行情,Viking Therapeutics, Inc.股价,Viking Therapeutics, Inc.股市,Viking Therapeutics, Inc.股票价格,Viking Therapeutics, Inc.股票交易,Viking Therapeutics, Inc.股票购买,Viking Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Viking Therapeutics, Inc.(VKTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Viking Therapeutics, Inc.(VKTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}